







Patient Name : RIMI NATTA Age : 35 Y 3 M 2 D

Gender : F

Lab Add. : Newtown, Kolkata-700156

Ref Dr. : Dr.MEDICAL OFFICER
Collection Date: 07/Jan/2023 09:03AM

**Report Date** : 07/Jan/2023 12:18PM



Test Name	Result	Unit	Bio Ref. Interval	Method	
CHLORIDE, BLOOD , .					
CHLORIDE,BLOOD	107.00	mEq/L	99-109 mEq/L	ISE INDIRECT	
SODIUM, BLOOD , GEL SERUM					
SODIUM,BLOOD	139.00	mEq/L	132 - 146 mEq/L	ISE INDIRECT	
POTASSIUM, BLOOD , GEL SERUM					
POTASSIUM,BLOOD	4.30	mEq/L	3.5-5.5 mEq/L	ISE INDIRECT	
UREA,BLOOD , GEL SERUM	21.4	mg/dL	19-49 mg/dL	Urease with GLDH	
CREATININE, BLOOD	0.55	mg/dL	0.5-1.1 mg/dL	Jaffe, alkaline picrate, kinetic	
PHOSPHORUS-INORGANIC, BLOOD, GEL SERUM					
PHOSPHORUS-INORGANIC,BLOOD	3.8	mg/dL	2.4-5.1 mg/dL	Phosphomolybdate/UV	
THYROID PANEL (T3, T4, TSH), GEL SERUM					
T3-TOTAL (TRI IODOTHYRONINE)	1.04	ng/ml	0.60-1.81 ng/ml	CLIA	
T4-TOTAL (THYROXINE)	5.6	μg/dL	3.2-12.6 μg/dL	CLIA	
TSH (THYROID STIMULATING HORMONE)	2.22	μIU/mL	0.55-4.78 μIU/mL	CLIA	

Serum TSH levels exhibit a diurnal variation with the peak occurring during the night and the nadir, which approximates to 50% of the peak value, occurring between 1000 and 1600 hours.[1,2]

#### References:

- 1. Bugalho MJ, Domingues RS, Pinto AC, Garrao A, Catarino AL, Ferreira T, Limbert E and Sobrinho L. Detection of thyroglobulin mRNA transcripts in peripheral blood of
- individuals with and without thyroid glands: evidence for thyroglobulin expression by blood cells. Eur J Endocrinol 2001;145:409-13.
- 2. Bellantone R, Lombardi CP, Bossola M, Ferrante A,Princi P, Boscherini M et al. Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrence varies according to the histologic type: results of a prospective study. Cancer 2001;92:2273-9.

# **BIOLOGICAL REFERENCE INTERVAL**: [ONLY FOR PREGNANT MOTHERS]

Trimester specific TSH LEVELS during pregnancy:

FIRST TRIMESTER:  $0.10-3.00~\mu$  IU/mL SECOND TRIMESTER: 0.20 -3.50  $\mu$  IU/mL THIRD TRIMESTER: 0.30 -3.50  $\mu$  IU/mL

**References:** 

1. Erik K. Alexander, Elizabeth N. Pearce, Gregory A. Brent, Rosalind S. Brown, Herbert Chen, Chrysoula Dosiou, William A. Grobman, Peter Laurberg, John H. Lazarus, Susan J. Mandel, Robin P. Peeters, and Scott Sullivan. Thyroid. Mar 2017.315-389. http://doi.org/10.1089/thy.2016.0457









2. Kalra S, Agarwal S, Aggarwal R, Ranabir S. Trimester-specific thyroid-stimulating hormone: An indian perspective. Indian J Endocr Metab 2018;22:1-4.

Dr NEEPA CHOWDHURY MBBS MD (Biochemistry) Consultant Biochemist

Page 2 of 12









ESR (ERYTHROCYTE SEDIMENTATION RATE), EDTA WHOLE BLOOD

1stHour 20 mm/hr 0.00 - 20.00 mm/hr Westergren

Pr Mansi Gulati

Consultant Pathologist MBBS, MD, DNB (Pathology)

**Lab No.** : CHP/07-01-2023/SR7153846 Page 3 of 12









**URINE ROUTINE ALL, ALL, URINE** 

#### PHYSICAL EXAMINATION

COLOUR PALE YELLOW

APPEARANCE HAZY

#### **CHEMICAL EXAMINATION**

pH7.04.6 - 8.0Dipstick (triple indicator method)SPECIFIC GRAVITY1.0101.005 - 1.030Dipstick (ion concentration method)PROTEINNOT DETECTEDNOT DETECTEDDipstick (protein error of pH

indicators)/Manual

GLUCOSE NOT DETECTED NOT DETECTED Dipstick(glucose-oxidase-peroxidase

method)/Manual

KETONES (ACETOACETIC ACID, NOT DETECTED NOT DETECTED Dipstick (Legals test)/Manual

ACETONES (ACETOACETIC ACID, NOT DETECTED ACETONE)

BLOOD PRESENT(+++) NOT DETECTED Dipstick (pseudoperoxidase reaction)
BILIRUBIN NEGATIVE NEGATIVE Dipstick (azo-diazo reaction)/Manual

UROBILINOGEN NEGATIVE NEGATIVE Dipstick (diazonium ion reaction)/Manual

 NITRITE
 NEGATIVE
 NEGATIVE
 Dipstick (Griess test)

 LEUCOCYTE ESTERASE
 POSITIVE(+++)
 NEGATIVE
 Dipstick (ester hydrolysis reaction)

# **MICROSCOPIC EXAMINATION**

LEUKOCYTES (PUS CELLS)	13-15	/hpf	0-5	Microscopy
EPITHELIAL CELLS	20-25	/hpf	0-5	Microscopy
RED BLOOD CELLS	8-10	/hpf	0-2	Microscopy
CAST	NOT DETECTED	O	NOT DETECTED	Microscopy
CRYSTALS	NOT DETECTED	O	NOT DETECTED	Microscopy
BACTERIA	PRESENT(++)		NOT DETECTED	Microscopy
YEAST	NOT DETECTED	)	NOT DETECTED	Microscopy

#### Note

- 1. All urine samples are checked for adequacy and suitability before examination.
- 2. Analysis by urine analyzer of dipstick is based on reflectance photometry principle. Abnormal results of chemical examinations are confirmed by manual methods.
- 3. The first voided morning clean-catch midstream urine sample is the specimen of choice for chemical and microscopic analysis.
- 4. Negative nitrite test does not exclude urinary tract infections.
- 5. Trace proteinuria can be seen in many physiological conditions like exercise, pregnancy, prolonged recumbency etc.
- 6. False positive results for glucose, protein, nitrite, urobilinogen, bilirubin can occur due to use of certain drugs, therapeutic dyes, ascorbic acid, cleaning agents used in urine collection container.
- 7. Discrepancy between results of leukocyte esterase and blood obtained by chemical methods with corresponding pus cell and red blood cell count by microscopy can occur due to cell lysis.
- 8. Contamination from perineum and vaginal discharge should be avoided during collection, which may falsely elevate epithelial cell count and show presence of bacteria and/or yeast in the urine.

# BLOOD GROUP ABO+RH [GEL METHOD], EDTA WHOLE BLOOD

 ABO
 B
 Gel Card

 RH
 POSITIVE
 Gel Card

# TECHNOLOGY USED: GEL METHOD

#### ADVANTAGES:

- · Gel card allows simultaneous forward and reverse grouping.
- Card is scanned and record is preserved for future reference.
- · Allows identification of Bombay blood group.
- Daily quality controls are run allowing accurate monitoring.

#### Historical records check not performed.

**Lab No.** : CHP/07-01-2023/SR7153846 Page 4 of 12









Lab No. : SR7153846 Name : RIMI	NATTA		Age/G: 35 Y 3 M 2 D / F	Date: 07-01-2023	
CBC WITH PLATELET (THROMBOCYTE) COUNT, EDTA WHOLE BLOOD					
HEMOGLOBIN	12.8	g/dL	12 - 15	PHOTOMETRIC	
WBC	9.9	*10^3/µL	4 - 10	DC detection method	
RBC	4.12	*10^6/µL	3.8 - 4.8	DC detection method	
PLATELET (THROMBOCYTE) COUNT	210	*10^3/µL	150 - 450*10^3/μL	DC detection method/Microscopy	
DIFFERENTIAL COUNT					
NEUTROPHILS	65	%	40 - 80 %	Flowcytometry/Microscopy	
LYMPHOCYTES	26	%	20 - 40 %	Flowcytometry/Microscopy	
MONOCYTES	06	%	2 - 10 %	Flowcytometry/Microscopy	
EOSINOPHILS	03	%	1 - 6 %	Flowcytometry/Microscopy	
BASOPHILS	00	%	0-0.9%	Flowcytometry/Microscopy	
CBC SUBGROUP					
HEMATOCRIT / PCV	38.1	%	36 - 46 %	Calculated	
MCV	92.4	fl	83 - 101 fl	Calculated	
MCH	31.2	pg	27 - 32 pg	Calculated	
MCHC	33.7	gm/dl	31.5-34.5 gm/dl	Calculated	
RDW - RED CELL DISTRIBUTION WIDTH	14.3	%	11.6-14%	Calculated	
PDW-PLATELET DISTRIBUTION WIDTH	16.5	fL	8.3 - 25 fL	Calculated	
MPV-MEAN PLATELET VOLUME	9.9		7.5 - 11.5 fl	Calculated	
				n A.A.	

Dr. PANKTI PATEL MBBS , MD (PATHOLOGY) CONSULTANT PATHOLOGIST









Lab No. : SR7153846	Name : RIMI NATTA		Age/G: 35 Y 3 M 2 D / F	Date : 07-01-2023
URIC ACID, BLOOD, GEL	SERUM			
URIC ACID,BLOOD	4.70	mg/dL	2.6-6.0 mg/dL	Uricase/Peroxidase
LIPID PROFILE , GEL SERU	IM			
CHOLESTEROL-TOTAL	148.00	mg/dL	Desirable: < 200 mg/dL Borderline high: 200-239 mg/dL High: > or =240 mg/dL	Enzymatic
TRIGLYCERIDES	107.00	mg/dL	Normal:: < 150, BorderlineHigh::150-199, High:: 200-499, VeryHigh::>500	GPO-Trinder
HDL CHOLESTEROL	48.00	mg/dl	< 40 - Low 40-59- Optimum 60 - High	Elimination/catalase
LDL CHOLESTEROL DIREC	T 79.0	mg/dL	OPTIMAL: <100 mg/dL, Near optimal/ above optimal: 100-129 mg/dL, Borderline high: 130-159 mg/dL High: 160-189 mg/dL, Very high: >=190 mg/dL	Calculated
VLDL	21	mg/dl	< 40 mg/dl	Calculated
CHOL HDL Ratio	3.1		LOW RISK 3.3-4.4 AVERAGE RISK 4.47-7.1 MODERATE RISK 7.1-11.0 HIGH RISK >11.0	Calculated

Reference: National Cholesterol Education Program. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. May 16 2001;285(19):2486-97.

#### CALCIUM, BLOOD

CALCIUM,BLOOD 8,90 mg/dL 8.7-10.4 mg/dL Arsenazo III

#### PDF Attached

#### GLYCATED HAEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD

GLYCATED HEMOGLOBIN (HBA1C) 5.3 % \*\*\*FOR BIOLOGICAL REFERENCE INTERVAL

REFERENCE INTERVAL
DETAILS , PLEASE REFER TO
THE BELOW MENTIONED
REMARKS/NOTE WITH
ADDITIONAL CLINICAL
INFORMATION \*\*\*

HbA1c (IFCC) 34.0 mmol/mol HPLC

Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:

Low risk / Normal / non-diabetic : <5.7% (NGSP) / < 39 mmol/mol (IFCC) Pre-diabetes/High risk of Diabetes : 5.7%- 6.4% (NGSP) / 39 - < 48 mmol/mol (IFCC) Diabetics-HbA1c level : >/= 6.5% (NGSP) / > 48 mmol/mol (IFCC)

Analyzer used: Bio-Rad-VARIANT TURBO 2.0

Method: HPLC Cation Exchange

### Recommendations for glycemic targets

- Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.
- Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.
- Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
- Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.
- $\varnothing$  For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular disease . Action suggested >8% as it indicates poor control.
- Ø Some patients may benefit from HbA1c goals that are stringent.

Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover;

**Lab No.** : CHP/07-01-2023/SR7153846 Page 6 of 12









vitamin  $B_{12}$ / folate deficiency, presence of chronic renal or liver disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.

Reference: Glycated hemoglobin monitoring BMJ 2006; 333;586-8

#### References

- 1. Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online 1 March 2016. doi:10.7326/M15-3016.
- 2. Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077-1080.

#### GLUCOSE, FASTING, BLOOD, NAF PLASMA

GLUCOSE, FASTING 82

mg/dL

Impaired Fasting-100-125.

Gluc Oxidase Trinder

Diabetes- >= 126.

Fasting is defined as no caloric intake for at least 8 hours.

In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate test samples.

#### Reference

ADA Standards of Medical Care in Diabetes - 2020. Diabetes Care Volume 43, Supplement 1.

# TOTAL PROTEIN [BLOOD] ALB:GLO RATIO, .

TOTAL PROTEIN	6.80	g/dL	5.7-8.2 g/dL	BIURET METHOD
ALBUMIN	4.3	g/dL	3.2-4.8 g/dL	BCG Dye Binding
GLOBULIN	2.50	g/dl	1.8-3.2 g/dl	Calculated
AG Ratio	1.72		1.0 - 2.5	Calculated

DR. ANANNYA GHOSH MBBS, MD (Biochemistry) Consultant Biochemist

**Lab No.** : CHP/07-01-2023/SR7153846 Page 7 of 12





# DEPARTMENT OF CYTOPATHOLOGY PAP SMEAR REPORT

Lab No: P -69/23

Reporting System: The 2014 Bethesda System

**Specimen**: Conventional Cervical Pap Smear.

**Specimen Adequacy: Satisfactory for evaluation:** 

A satisfactory squamous component is present.

Endocervical or transformation zone component: Present.

Obscuring elements: Absent.

**General Categorization:** 

Negative for Intraepithelial Lesion / Malignancy (NILM).

**Non-Neoplastic Findings:** 

Moderate inflammation is noted in the background.

### INTERPRETATION / RESULTS: Negative for Intraepithelial Lesion / Malignancy (NILM).

Note: Pap smear cytology is a screening procedure. Findings should be correlated with colposcopic/local examination and ancillary findings.

As per current recommendation, women aged 30-65 years should be screened with both the HPV test and the Pap test, called "co-testing," as the preferred strategy. Screening with the Pap test alone every 3 years is still acceptable.

Ancillary Testing - For HPV testing using PCR from the same sample (only in case of LBC) request should come within 15 days from the reporting date.

\*\*\*Report relates to the item tested only.

Dr. PANKTI PATEL
MBBS , MD (PATHOLOGY)
CONSULTANT PATHOLOGIST





Patient Name : RIMI NATTA

**Age** : 35 Y 3 M 2 D

Gender : F

Lab Add. :

**Ref Dr.** : Dr.MEDICAL OFFICER

**Collection Date:** 

**Report Date** : 07/Jan/2023 11:33AM



# DEPARTMENT OF CARDIOLOGY REPORT OF E.C.G.

DATA HEART RATE	81	Bpm
PR INTERVAL	136	Ms
QRS DURATION	74	Ms
QT INTERVAL	354	Ms
QTC INTERVAL	412	Ms
AXIS P WAVE	48	Degree
QRS WAVE	59	Degree
T WAVE IMPRESSION	39 :	Degree Normal sinus rhythm, within normal limits.

Dr. SOUMEN MAJUMDAR
Department of Non-invasive
Cardiology





Patient Name : RIMI NATTA

**Age** : 35 Y 3 M 2 D

**Gender** : F **Report Date** : 07/Jan/2023 03:04PM



# X-RAY REPORT OF CHEST (PA)

Lab Add.

**Collection Date:** 

: Dr.MEDICAL OFFICER

Ref Dr.

# **FINDINGS:**

No active lung parenchymal lesion is seen.

Both the hila are normal in size, density and position.

Mediastinum is in central position. Trachea is in midline.

Domes of diaphragm are smoothly outlined. Position is within normal limits.

Lateral costo-phrenic angles are clear.

The cardio-thoracic ratio is normal.

Bony thorax reveals no definite abnormality.

# **IMPRESSION:**

Normal study.

DR. SUDIPTA SARKAR MBBS,MD (Radio- Diagnosis) DNB (Radio-Diagnosis), MNAMS EDIR, D-ICRI, FRCR (UK)

Page 10 of 12





**Lab No.** : CHP/07-01-2023/SR7153846 **Lab Add.** 

Patient Name : RIMI NATTA Ref Dr. : Dr.MEDICAL OFFICER

Age : 35 Y 3 M 2 D Collection Date:

**Gender** : F **Report Date** : 07/Jan/2023 11:11AM



Page 11 of 12

# DEPARTMENT OF ULTRASONOGRAPHY REPORT ON EXAMINATION OF WHOLE ABDOMEN

# **LIVER**

Liver is nomal in size (134 mm) having normal shape, **shows grade I fatty changes of liver.** No focal parenchymal lesion is evident.Intrahepatic biliary radicles are not dilated. Branches of portal vein are normal.

# **PORTA**

The appearance of porta is normal. Common Bile duct is 3.2 mm. with no intraluminal pathology (Calculi /mass) could be detected at its visualsed part. Portal vein is normal (8.6 mm.) at porta.

# **GALL BLADDER**

Gallbladder is physiologically distended. Wall thickness appears normal. No intraluminal pathology (Calculi/mass) could be detected. Sonographic Murphys sign is negative.

# **PANCREAS**

Echogenecity appears within limits, without any focal lesion. Shape, size & position appears normal. No Calcular disease noted. Pancreatic duct is not dilated. No peri-pancreatic collection of fluid noted.

### **SPLEEN**

Spleen is normal in size (80 mm). Homogenous and smooth echotexture without any focal lesion. Splenic vein at hilum appears normal. No definite collaterals could be detected.

# **KIDNEYS**

Both the kidneys are normal in shape, size (Rt. kidney 118 mm x 35 mm. & Lt. kidney 112 mm x 47 mm.) axes & position. Cortical echogenecity appears normal maintaining cortico-medullary & cortico-hepatic differentiation. Margin is regular and cortical thickness is uniform. No calcular disease noted. No hydronephrotic changes detected. Visualised part of upper ureters are not dilated.

# **URINARY BLADDER**

Urinary bladder is distended, wall thickness appeared normal.No intraluminal pathology (calculi/mass) could be detected.

### **UTERUS**

Uterus is anteverted, normal in size (67 mm. x 51 mm. x 43 mm.) ET - 13.7 mm. Myometrium appears smooth & homogenous without any detectable/sizable focal lesion.

Cervix looks normal.

Pouch of Douglas is free.

# **ADNEXA**

Adnexa appear clear with no obvious mass lesion could be detected.

# **OVARIES**

Ovaries are normal in size, shape, position, margin and echotexture.

Right ovary measures 40 mm x 18 mm.





Patient Name : RIMI NATTA

**Age** : 35 Y 3 M 2 D

Gender : F Report Date : 07/Jan/2023 11:11AM

Report Date . 07/3ali/2023 11.11A

Left Ovary measures 40 mm x 18 mm.

# RETROPERITONEUM, PERITONEUM & LOWER PLEURAL SPACE

No ascites noted. No definite evidence of any mass lesion detected. No detectable evidence of enlarged lymph nodes noted. Visualised part of aorta & IVC are within normal limit. No effusion noted at costo-phrenic angles.

Lab Add. Ref Dr.

**Collection Date:** 

: Dr.MEDICAL OFFICER

# **IMPRESSION**

Grade I fatty liver.

# **Kindly note**

- Ø Ultrasound is not the modality of choice to rule out subtle bowel lesion.
- Ø Please Intimate us for any typing mistakes and send the report for correction within 7 days.
- Ø The science of Radiological diagnosis is based on the interpretation of various shadows produced by both the normal and abnormal tissues and are not always conclusive. Further biochemical and radiological investigation & clinical correlation is required to enable the clinician to reach the final diagnosis.

The report and films are not valid for medico-legal purpose.

Patient Identity not verified.

DR. HARSHA SAHU MBBS, DMRD, DNB(Radiodiagnosis) Consultant Radiologist

Reg No WBMC-88013

**Lab No.** : CHP/07-01-2023/SR7153846 Page 12 of 12

# SURAKSHA DIAGNOSTIC, RAJARHAT, KOLKATA. BIO-RAD VARIANT TURBO CDM 5.4 s/n 15893

# PATIENT REPORT V2TURBO A1c 2.0

Patient Data Analysis Data

Sample ID: C02135958341 Analysis Performed: 07/JAN/2023 12:15:25

 Patient ID:
 SR7153846
 Injection Number:
 7421U

 Name:
 Run Number:
 227

 Physician:
 Rack ID:
 0003

 Sex:
 Tube Number:
 2

DOB: Report Generated: 07/JAN/2023 12:29:09

Operator ID: ANAMIKA

Comments:

	NGSP		Retention	Peak
Peak Name	%	Area %	Time (min)	Area
A1a		1.2	0.156	15674
A1b		1.1	0.218	14158
F		0.8	0.266	10264
LA1c		1.7	0.401	22263
A1c	5.3		0.511	55833
P3		3.5	0.789	45992
P4		1.3	0.870	17206
Ao		86.1	0.998	1127384

Total Area: 1,308,775

# HbA1c (NGSP) = 5.3 % HbA1c (IFCC) = 34 mmol/mol

